Published in Br J Cancer on November 01, 1991
High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med (1977) 15.39
The pathogenesis of atherosclerosis--an update. N Engl J Med (1986) 14.59
Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A (1979) 11.19
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. J Immunol (1985) 4.41
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Serum cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA (1988) 1.49
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation (1987) 1.13
Lymphocyte-conditioned medium protects human monocyte-macrophages from cholesteryl ester accumulation. Proc Natl Acad Sci U S A (1982) 0.97
The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab (1989) 0.94
Lymphokines secreted by an established lymphocyte line modulate receptor-mediated endocytosis in macrophages derived from human monocytes. J Immunol (1983) 0.93
Interleukin 2 and its receptor: structure, function and therapeutic potential. Blood Rev (1987) 0.84
Effects of monocyte macrophages stimulation on hepatic lipoprotein receptors. Biochim Biophys Acta (1988) 0.79
Hypocholesterolemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins. J Clin Oncol (1989) 0.79
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy. Lancet (1999) 12.51
Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med (1976) 9.68
A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage (1999) 2.52
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol (1997) 1.94
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol (2012) 1.78
Laparoscopy and laparotomy combined with bone marrow biopsy in staging Hodgkin's disease. Br Med J (1975) 1.52
Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat (1985) 1.51
Are surgical adjuvant trials altering the course of breast cancer? Semin Oncol (1978) 1.49
Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations. Int J Biol Markers (1998) 1.45
Should the skin prick test to horse be included in the standard panel for the diagnosis of respiratory allergy? J Investig Allergol Clin Immunol (2009) 1.42
A clinical study of the pineal hormone melatonin in patients with growth hormone or prolactin secreting pituitary tumours. Eur J Med (1992) 1.38
Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers (2004) 1.35
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol (1999) 1.27
Efficacy and safety of levodropropizine and dihydrocodeine on nonproductive cough in primary and metastatic lung cancer. Eur Respir J (1998) 1.20
Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol (1994) 1.15
The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol (2013) 1.12
Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res (1999) 1.12
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. Ann Oncol (2010) 1.10
Urticaria and urticaria related skin condition/disease in children. Eur Ann Allergy Clin Immunol (2008) 1.08
Dependence of fibroblast autofluorescence properties on normal and transformed conditions. Role of the metabolic activity. Photochem Photobiol (1999) 1.08
Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol (2007) 1.06
Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur J Cancer Clin Oncol (1989) 1.05
Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy. Endoscopy (2012) 1.04
Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol (2012) 1.02
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. Eur J Cancer (1999) 1.00
Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol (1983) 0.99
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol (2012) 0.99
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents (2001) 0.98
Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol (2012) 0.98
Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol (2006) 0.97
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Br J Cancer (2001) 0.96
Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer (1986) 0.95
Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms. J Biol Regul Homeost Agents (2006) 0.95
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer (1999) 0.95
Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2. Eur J Cancer (1991) 0.95
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol (2009) 0.95
A single-step staining procedure for the detection and sorting of unfixed apoptotic thymocytes. Eur J Histochem (1993) 0.93
Early acute necrosis, delayed apoptosis and cytoskeletal breakdown in cultured cerebellar granule neurons exposed to methylmercury. J Neurosci Res (2000) 0.93
Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. Int J Colorectal Dis (2012) 0.92
Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans. Nat Immun (1998) 0.92
Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J Biol Regul Homeost Agents (2000) 0.91
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology (1996) 0.91
Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori (1988) 0.91
The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature. Eur J Surg Oncol (2011) 0.90
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol (2002) 0.90
Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology (1991) 0.90
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin. Support Care Cancer (1997) 0.89
Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer (1995) 0.89
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. Support Care Cancer (1997) 0.89
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer. Br J Cancer (1992) 0.89
Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. Gynecol Oncol (1996) 0.88
The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer (1990) 0.88
Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats. Eur J Histochem (2012) 0.88
Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Ann Oncol (2006) 0.87
[Clinical response and survival in metastatic renal carcinoma during subcutaneous administration of interleukin-2 alone. Subcutaneous Il-2 in renal carcinoma]. Arch Ital Urol Androl (1997) 0.87
Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol (2009) 0.87
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms. Cancer (1994) 0.87
A review on cancer--psychospiritual status interactions. Neuro Endocrinol Lett (2001) 0.87
Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers (2003) 0.87
Second malignancies after CMF for resectable breast cancer. J Clin Oncol (1987) 0.87
Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. NCI Monogr (1986) 0.87
Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res (2009) 0.87
A spiritual approach in the treatment of cancer: relation between faith score and response to chemotherapy in advanced non-small cell lung cancer patients. In Vivo (2008) 0.87
Spontaneous apoptosis of thymocytes is uncoupled with progression through the cell cycle. Exp Cell Res (1996) 0.86
Prolactin response to thyrotropin-releasing hormone in early and advanced human breast cancer. Tumori (1986) 0.86
Pineal gland and tumor cell kinetics: serum levels of melatonin in relation to Ki-67 labeling rate in breast cancer. Oncology (1990) 0.86
Evidence for altered opioid activity in patients with cancer. Br J Cancer (1987) 0.86